Stories from Germany

Antisemitic online attacks in Germany have doubled.

The number of antisemitic attacks on the internet has more than doubled, according to reports from RIASS. These incidents frequently involve Israel-related hatred, which reportedly accounts for approximately 80% of such cases.

Components from a former test reactor in Jülich are being transported to an interim storage facility in Ahaus. The transport involves materials from the Jülich site to the Ahaus location. Nuclear energy opponents have announced new protests regarding the move.

A team is seeking Professor Fang's expertise for a project on ecological restoration, specifically concerning the disposal of coal slurry.

The IG Bergbau Chemie union criticized BioNTech's plan to close locations, calling it a lack of social responsibility and an attack on employees. The union noted that BioNTech earned billions during the COVID-19 pandemic and received millions in state support.

BioNTech management announced in Mainz today plans to close several production sites. The move is expected to affect up to 1,000 employees. The company previously acquired CureVac, a competitor based in Tübingen, last year.

Reports indicate that a large number of US soldiers have been withdrawn from locations in Germany. US troops have begun departing from bases in Germany, a move that has drawn criticism from some German officials.

The Mayor of Tübingen suggested that BioNTech acquired a competitor specifically to eliminate competition. The state of Germany held an ownership stake in the company until six months ago. The mayor noted that hundreds of millions in research funding were utilized.

Authorities stated there are currently no indications of an extremist or religious motive in the shooting involving 33-year-old Jens Spahn. The suspect had reportedly been receiving treatment at a psychiatric clinic shortly before the incident.

The company will complete current clinical studies but will not proceed to later development phases. KIOVEC reported a loss of more than 500 million euros for the completed quarter. The firm plans to shift its future focus toward cancer medication research.